Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068661 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL1705904 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| P-Xylene SCHEMBL8660591 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL34 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL11432043 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL31313 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL29991938 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| Ammonia Solution, Strong SCHEMBL4657790 | 0.86 | GAA (0.59) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| Water SCHEMBL1160667 | 0.86 | GAA (0.59) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL3180429 | 0.86 | GAA (0.59) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795176-B | Salt of cephalosporin derivative, crystalline solid thereof and process for producing the same | 盐野义制药株式会社 | 2020-11-10 | — | — | CN | disclosed |
| US-10004750-B2 | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof | SHIONOGI & CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170281638-A1 | A SALT OF CEPHALOSPORIN DERIVATIVE, ITS CRYSTALLINE SOLID AND A METHOD OF MANUFACTURING THEREOF | SHIONOGI & CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| EP-3190115-A1 | SALT OF CEPHALOSPORIN DERIVATIVE, CRYSTALLINE SOLID FORM OF SAME AND METHOD FOR PRODUCING SAME | Shionogi & Co., Ltd. (JP) | 2017-07-12 | — | — | EP | disclosed |
| CN-106795176-A | Salt of cephalosporin derivative, crystalline solid thereof and process for producing the same | 盐野义制药株式会社 | 2017-05-31 | — | — | CN | disclosed |
| US-20100186763-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE LAMBDA-CARRAGEENAN POLYSACCHARIDE AND INORGANIC PARTICLES | L'OREAL S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| US-4287092-A | Acid catalysis of resin foundry binders | CL INDUSTRIES, INC. (US) | 1981-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004750-B2 | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof | SHARPIN, CEL, CHLSN | ALDH1A1 2543/4885SMN1; SMN2 3842/4885LMNA 2676/4885 |
| US-20100186763-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE LAMBDA-CARRAGEENAN POLYSACCHARIDE AND INORGANIC PARTICLES | POLL, ALG1, YWHAZ | ALDH1A1 3623/4885SMN1; SMN2 4231/4885LMNA 3598/4885 |
| US-20170281638-A1 | A SALT OF CEPHALOSPORIN DERIVATIVE, ITS CRYSTALLINE SOLID AND A METHOD OF MANUFACTURING THEREOF | CEL, SEPTIN7, SHARPIN | ALDH1A1 2539/4885SMN1; SMN2 4042/4885LMNA 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.